| Bioactivity | Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders[1]. | |||||||||
| Target | FXR. | |||||||||
| Invitro | Gly-β-MCA, a bile acid, is a potent, sable and intestine-selective and farnesoid X receptor (FXR) inhibitor[1].Gly-β-MCA (Gly-MCA, ) is resistant to hydrolysis by BSH[1]. | |||||||||
| In Vivo | Gly-β-MCA (Gly-MCA, p.o. 10 and 50 mg/kg) prevents and treats diet-induced and genetic obesity, along with insulin resistance and hepatic steatosis without systemic, hepatic or intestinal toxicities in mice[1].Gly-MCA does not increase faecal LCN-2 levels, indicating that Gly-MCA does not induce intestinal inflammation[1]. | |||||||||
| Name | Gly-β-MCA | |||||||||
| CAS | 66225-78-3 | |||||||||
| Formula | C26H43NO6 | |||||||||
| Molar Mass | 465.62 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Jiang C, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015 Dec 15;6:10166. |